vector design, assessing genotoxicity, and identifying optimal experimental protocols for in vivo and in vitro strategies. Whitelab Genomics guides its clients through the in-silico development phases, allowing them to quickly develop target vectors and payloads while saving valuable time needed to provide patients with access to new genomic therapies.